Review summary
Teaching objective: Alcohol use disorder with chronic kidney disease and hypertension in a working writer: a 39-year-old novelist who writes a thousand words every morning on his ranch comes in tired, with swollen ankles, and is found to have a blood pressure of 158/98, an eGFR of 43 and albumin in the urine, and to drink heavily. The episode covers the AUDIT, the DSM-5-TR criteria and PEth; liver tests, FIB-4 and elastography; outpatient withdrawal management with a withdrawal-risk score and thiamine; medicine for alcohol use disorder chosen with kidney function in mind (naltrexone, with acamprosate needing a lower dose at his creatinine clearance and avoided below 30 mL/min); CKD staging by KDIGO 1913 with eGFR and urine albumin, the cause (hypertension and two years of daily naproxen, without stones or gout), ultrasound, the kidney failure risk equation and mineral tests; blood pressure under KDIGO 1910 and the 1914 AHA/ACC guideline with an angiotensin receptor blocker at the maximum dose and potassium and creatinine checks; an SGLT2 inhibitor once he is abstinent, because heavy drinking raises the risk of ketoacidosis; analgesic and opioid safety, with no NSAIDs, a lower acetaminophen limit and naltrexone's opioid blockade; the safety assessment and lethal-means counseling; tobacco; vaccinations in kidney and liver disease; and a plan that protects his morning writing hours.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| January 12, 1876 | Born in San Francisco as John Griffith Chaney; raised by his mother and his stepfather, John London. | CLM-0001 |
| 1891 to 1894 | Works from boyhood as an oyster pirate, fish patrolman, seaman and tramp. | CLM-0002 |
| 1897 to 1898 | Klondike gold rush; comes home with scurvy. | CLM-0003 |
| April 7, 1900 | Marries; two daughters are born in 1901 and 1902; divorced in 1905, he marries again in November 1905. | CLM-0016 |
| 1903 | The Call of the Wild brings international fame; writes 1,000 words a day for the rest of his life. | CLM-0004 |
| 1905 | Buys the first land of his ranch at Glen Ellen. | CLM-0005 |
| April 23, 1907 | Sails on the Snark; sores, swollen peeling hands and a silvery skin in the South Pacific; gives up the voyage in Australia. | CLM-0006, CLM-0007 |
| July 1913 | Appendectomy; serious kidney damage found. | CLM-0009 |
| August 22, 1913 | Wolf House burns; John Barleycorn is published the same year. | CLM-0005, CLM-0008 |
| April 1914 | War correspondent at Vera Cruz; ill with dysentery and rheumatism. | CLM-0010 |
| July 22, 1915 | Returns from five months in Hawaii; sails there again on December 16, 1915. | CLM-0011 |
| November 22, 1916 | Dies at his ranch at 40 of uraemia following renal colic; he had refused his doctors' advice to stop drinking and change his habits. A later story of a morphine overdose or suicide is disputed. | CLM-0012, CLM-0013, CLM-0014, CLM-0015 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | He was born on January 12, 1876, in San Francisco, and his birth certificate named him John Griffith Chaney. His mother, Flora Wellman, had lived with William Chaney, an astrologer, who left before the birth; she married John London, who adopted and raised the boy. | confirmed | Jack London: A Brief Biography (Education Resources, History on Jack London) supports Leal L. The Life of Jack London (docent presentation text and supplemental information, 2017) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports HISTMED Master Roster v3 context |
| D | He grew up poor and worked from boyhood: an oyster pirate at 15, on the fish patrol at 16, an able-bodied seaman at 17, and a tramp crossing America at 18, when he spent a month in jail. Anchors the social history of a man who rose from poverty. |
confirmed | Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| D | He went to the Klondike gold fields in 1897, at 21, and came home with very little after suffering scurvy. Past nutritional illness; no lasting effect is used in the modern episode. |
confirmed | Leal L. The Life of Jack London (docent presentation text and supplemental information, 2017) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| D | He became internationally famous with The Call of the Wild (1903) and The Sea Wolf (1904), completed more than 50 books between 1900 and 1916, was at his peak the highest paid writer in the United States, and pushed to write 1,000 words a day wherever he was. Anchors the modern writing schedule. |
confirmed | Jack London: A Brief Biography (Education Resources, History on Jack London) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| D | From 1905 he bought land at Glen Ellen in the Sonoma Valley and built up his Beauty Ranch; Wolf House, his nearly finished stone and redwood home, burned on August 22, 1913, a crushing financial loss. The loss left him depressed, but he forced himself back to work. Anchors the setting, the financial pressure and the social history; the word 'depressed' is the park's, not a diagnosis. |
confirmed | Jack London: A Brief Biography (Education Resources, History on Jack London) supports Jack London State Historic Park supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| D | On the voyage of his yacht Snark through the South Pacific (1907 to 1909), in the Solomon Islands he had sores that a physician in Fiji called yaws and a missionary said were not; his hands swelled and peeled and his toenails thickened, a malady the Australian specialists could not name; he spent five weeks in hospital in Australia, gave up the voyage, and blamed tropical light. He also had a 'silvery skin' that doctors called by old names for leprosy, which cleared without treatment in California. His own published account, recorded as he gave it; the modern diagnosis of these conditions is not settled (CLM-0007). |
confirmed | London J. The Cruise of the Snark (Project Gutenberg eBook #2512) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports Jack London: A Brief Biography (Education Resources, History on Jack London) supports |
| R | Physicians writing since have interpreted his illnesses differently: the 'silvery skin' has been read as psoriasis; one review proposed that mercury used to treat yaws damaged his kidneys and caused a dermatitis of the hands, feet and face; others suggested lupus, gout, and the effects of tobacco, alcohol and diet on his blood pressure and kidneys. None is established. Retrospective and disputed; none is used as a diagnosis for him. The modern episode's kidney disease has its own synthetic cause. |
disputed | Leal L. The Death of Jack London: Fact and Fiction (2016) supports Bomback AS, Klemmer PJ. Jack London's "chronic interstitial nephritis": a historical differential diagnosis. Pharos Alpha Omega Alpha Honor Med Soc 2008;71(1):26-30 (PMID 18246783) supports Bomback AS, Klemmer PJ. Jack London's "mysterious malady". Am J Med 2007;120(5):466-467 (PMID 17466662) supports Denko CW. Jack London. A modern analysis of his mysterious disease. J Rheumatol 1993;20(10):1760-1763 (PMID 8295191) supports Aronica JC, Norton SA. The Snark and the Skin: Jack London's Pacific Voyage. JAMA Dermatol 2015;151(9):1016 (PMID 26352126) context |
| D | In John Barleycorn (1913) he wrote of his drinking from the first time he got drunk, at five years old. He held that he was no born alcoholic and had acquired the taste, and described how at the ranch, after writing his thousand words between nine and eleven each morning, he began to take a cocktail before midday dinner and then alone, 'not for the sake of the taste, but for the effect of the drink.' His own account of heavy drinking, recorded in his words; it anchors the modern alcohol use disorder but does not make a diagnosis for him. |
confirmed | London J. John Barleycorn (1913) (Project Gutenberg eBook #318) supports Jack London: A Brief Biography (Education Resources, History on Jack London) context HISTMED Master Roster v3 context |
| D | In July 1913 he had his appendix removed, and serious kidney damage was found; his physician diagnosed a significant kidney problem at that time. Anchors the modern chronic kidney disease; the nature of the kidney disease is not documented in the sources read. |
confirmed | Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports Leal L. The Death of Jack London: Fact and Fiction (2016) supports |
| D | In 1914 he went to Vera Cruz as a war correspondent in the Mexican Revolution and was ill with dysentery and rheumatism. Past illnesses; they anchor his joint pain in the modern episode but no diagnosis is made from them. |
confirmed | Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports Jack London: A Brief Biography (Education Resources, History on Jack London) supports |
| D | He spent February 24 to July 22, 1915, in Hawaii and sailed there again on December 16, 1915; his health was described that year as declining. Anchors the dates of the modern episode, set at the ranch between the two stays in Hawaii. |
confirmed | Leal L. The Life of Jack London (docent presentation text and supplemental information, 2017) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| D | His doctors urged him to change his work habits and diet, stop all alcohol and get more exercise, and he refused. Documented history; no undated advice is used in the modern episode. |
confirmed | Jack London: A Brief Biography (Education Resources, History on Jack London) supports |
| D | He died at his ranch on November 22, 1916, at 40. His death certificate, signed by his own physician, gave the cause as uraemia following renal colic; his physicians' bulletin described a gastro-intestinal type of uraemia, with coma, after he was taken ill in the night. Documented cause of death; it anchors the modern kidney disease but nothing about his death is used in the modern episode. |
confirmed | Leal L. The Death of Jack London: Fact and Fiction (2016) supports Jack London: A Brief Biography (Education Resources, History on Jack London) supports Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports HISTMED Master Roster v3 context |
| R | Whether morphine contributed to his death is disputed. A story that he took his own life began after his death and was spread by a 1938 biographical novel that described empty morphine vials; his attending physicians denied it, and historians, a pharmacist and physicians have argued against it, noting that he had taken morphine for pain for some time and that failing kidneys would have let a usual dose build up. Disputed; the record takes neither side, and nothing about suicide or overdose is used in the modern episode. Recorded only as later history. |
disputed | Leal L. The Death of Jack London: Fact and Fiction (2016) supports |
| D | He married Bess Maddern in 1900; their daughters Joan and Bess were born in 1901 and 1902, and the marriage ended in divorce in 1905. He married Charmian Kittredge in November 1905. Documented family history; no relative has any statement, decision or health fact in the modern episode. |
confirmed | Stumpf A, Leal L, Hayes G, Houghton L. Interpreting the History of Jack London (docent presentation, 2008, revised 2018) supports |
| R | The roster's leads of depression and probable bipolar disorder are not documented as diagnoses in the sources read. Not used as diagnoses; the modern episode screens mood with the PHQ-9. |
disputed | HISTMED Master Roster v3 context Jack London: A Brief Biography (Education Resources, History on Jack London) context |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Tiredness, ankle swelling and high blood pressure (158/98 mmHg) with a raised creatinine (1.98 mg/dL, eGFR 43) and albumin in the urine (240 mg/g), found at intake; a creatinine of 1.7 mg/dL at an insurance examination about fourteen months ago, by his account; chronicity and cause under evaluation with a nephrology consultation | resolved | confirmed | active | CLM-0009 |
| S | Chronic kidney disease, stage G3b A2 (eGFR 42 to 43, urine albumin 240 mg/g), most likely from hypertension with a contribution from two years of daily naproxen; kidneys of normal size, without stones or obstruction; urine sediment bland; synthetic modern diagnosis linked to his documented kidney disease | active | confirmed | both_with_link | CLM-0009 |
| S | Hypertensive chronic kidney disease, untreated until intake | active | confirmed | active | CLM-0009 |
| S | Alcohol use disorder, severe (seven DSM-5-TR criteria): a bottle of whisky or more most days for years, a morning drink to steady his hands, failed attempts to cut down, and drinking despite knowing it harms his health; AUDIT 27; PEth 410 ng/mL | active | confirmed | active | CLM-0008 |
| S | Alcohol-associated fatty liver without advanced fibrosis (liver stiffness 7.2 kPa; steatosis on ultrasound); FIB-4 2.28 at intake | active | confirmed | active | CLM-0008 |
| S | Daily self-directed naproxen for knee and back pain for about two years, stopped at intake; acetaminophen in its place | resolved | confirmed | active | CLM-0010 |
| S | Cigarette smoking, about ten a day; not ready to stop while he stops drinking | active | confirmed | active | CLM-0007 |
| S | Right ankle sprain (lateral ligaments, moderate), from stepping into a burrow while walking the pasture; Ottawa ankle rules negative; healed in about four weeks | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1915-08-04 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1915-08-04 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-08-04 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1915-08-04 | Urea nitrogen [Mass/volume] in Serum or Plasma | 28 mg/dL (high) Reference 7-20 mg/dL |
http://loinc.org · 3094-0 |
| S | 1915-08-04 | Creatinine [Mass/volume] in Serum or Plasma | 1.98 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-08-04 | Glucose [Mass/volume] in Serum or Plasma | 94 mg/dL Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1915-08-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 43 mL/min/1.73 m² (low) Reference 45 to 59 is G3a; 30 to 44 is G3b |
http://loinc.org · 98979-8 |
| S | 1915-08-04 | Albumin/Creatinine [Mass Ratio] in Urine | 240 mg/g (high) Reference Below 30 mg/g A1; 30 to 300 A2; above 300 A3 |
http://loinc.org · 9318-7 |
| S | 1915-08-04 | Urate [Mass/volume] in Serum or Plasma | 8.4 mg/dL (high) Reference 4-8 mg/dL |
http://loinc.org · 3084-1 |
| S | 1915-08-04 | Calcium [Mass/volume] in Serum or Plasma | 9.2 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 1915-08-04 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 mg/dL Reference 2.5-4.5 mg/dL |
http://loinc.org · 2777-1 |
| S | 1915-08-04 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 74 pg/mL (high) Reference 15-65 pg/mL |
http://loinc.org · 2731-8 |
| S | 1915-08-04 | Hemoglobin [Mass/volume] in Blood | 13.6 g/dL Reference 13-17 g/dL |
http://loinc.org · 718-7 |
| S | 1915-08-04 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 fL (high) Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1915-08-04 | Platelets [#/volume] in Blood by Automated count | 182 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 1915-08-04 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 68 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 1915-08-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 41 U/L Reference 9-46 U/L |
http://loinc.org · 1742-6 |
| S | 1915-08-04 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 186 U/L (high) Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 1915-08-04 | Albumin [Mass/volume] in Serum or Plasma | 4.1 g/dL Reference 3.5-5 g/dL |
http://loinc.org · 1751-7 |
| S | 1915-08-04 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 mg/dL Reference 0.2-1.2 mg/dL |
http://loinc.org · 1975-2 |
| S | 1915-08-04 | INR in Platelet poor plasma by Coagulation assay | 1 Reference 0.9-1.1 |
http://loinc.org · 6301-6 |
| S | 1915-08-04 | Phosphatidylethanol [Mass/volume] in Blood | 410 ng/mL (high) Reference Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking |
http://loinc.org · 74661-0 |
| S | 1915-08-04 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4% Reference <=5.6% |
http://loinc.org · 4548-4 |
| S | 1915-08-04 | Cholesterol [Mass/volume] in Serum or Plasma | 214 mg/dL (high) Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 1915-08-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 mg/dL Reference >=40 mg/dL |
http://loinc.org · 2085-9 |
| S | 1915-08-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 mg/dL Reference <=129 mg/dL |
http://loinc.org · 13457-7 |
| S | 1915-08-04 | Triglyceride [Mass/volume] in Serum or Plasma | 140 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 1915-08-04 | Total score [AUDIT] | 27 | http://loinc.org · 75624-7 |
| S | 1915-08-04 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | http://loinc.org · 44261-6 |
| S | 1915-08-04 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | http://loinc.org · 70274-6 |
| S | 1915-08-18 | Potassium [Moles/volume] in Serum or Plasma | 4.9 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 2.04 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 42 mL/min/1.73 m² (low) Reference 45 to 59 is G3a; 30 to 44 is G3b |
http://loinc.org · 98979-8 |
| S | 1915-08-18 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 49 U/L (high) Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 1915-08-18 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36 U/L Reference 9-46 U/L |
http://loinc.org · 1742-6 |
| S | 1915-08-18 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 141 U/L (high) Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 1915-09-15 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1915-09-15 | Potassium [Moles/volume] in Serum or Plasma | 4.8 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-09-15 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1915-09-15 | Creatinine [Mass/volume] in Serum or Plasma | 1.96 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-09-15 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 44 mL/min/1.73 m² (low) Reference 45 to 59 is G3a; 30 to 44 is G3b |
http://loinc.org · 98979-8 |
| S | 1915-09-15 | Albumin/Creatinine [Mass Ratio] in Urine | 128 mg/g (high) Reference Below 30 mg/g A1; 30 to 300 A2; above 300 A3 |
http://loinc.org · 9318-7 |
| S | 1915-09-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 1915-09-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 U/L Reference 9-46 U/L |
http://loinc.org · 1742-6 |
| S | 1915-09-15 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 82 U/L (high) Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 1915-09-15 | Phosphatidylethanol [Mass/volume] in Blood | 36 ng/mL (high) Reference Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking |
http://loinc.org · 74661-0 |
| S | 1915-09-15 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 ng/mL (low) Reference Below 20 ng/mL deficient; 20 to 29 insufficient |
http://loinc.org · 62292-8 |
| S | 1915-09-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | http://loinc.org · 44261-6 |
| S | 1915-09-29 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | http://loinc.org · 55758-7 |
| S | 1915-10-13 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1915-10-13 | Potassium [Moles/volume] in Serum or Plasma | 5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-10-13 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1915-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.95 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 44 mL/min/1.73 m² (low) Reference 45 to 59 is G3a; 30 to 44 is G3b |
http://loinc.org · 98979-8 |
| S | 1915-10-13 | Phosphatidylethanol [Mass/volume] in Blood | 8 ng/mL Reference Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking |
http://loinc.org · 74661-0 |
| S | 1915-10-27 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1915-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1915-10-27 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 mmol/L Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 1915-10-27 | Urea nitrogen [Mass/volume] in Serum or Plasma | 24 mg/dL (high) Reference 7-20 mg/dL |
http://loinc.org · 3094-0 |
| S | 1915-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 2.13 mg/dL (high) Reference 0.74-1.35 mg/dL |
http://loinc.org · 2160-0 |
| S | 1915-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1910)/1.73 sq M | 40 mL/min/1.73 m² (low) Reference 45 to 59 is G3a; 30 to 44 is G3b |
http://loinc.org · 98979-8 |
| S | 1915-10-27 | Albumin/Creatinine [Mass Ratio] in Urine | 96 mg/g (high) Reference Below 30 mg/g A1; 30 to 300 A2; above 300 A3 |
http://loinc.org · 9318-7 |
| S | 1915-10-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 U/L Reference 10-40 U/L |
http://loinc.org · 1920-8 |
| S | 1915-10-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 U/L Reference 9-46 U/L |
http://loinc.org · 1742-6 |
| S | 1915-10-27 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 54 U/L Reference 8-61 U/L |
http://loinc.org · 2324-2 |
| S | 1915-10-27 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 96 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 1915-10-27 | Phosphatidylethanol [Mass/volume] in Blood | 6 ng/mL Reference Below 20 ng/mL abstinence or light drinking; above 200 heavy drinking |
http://loinc.org · 74661-0 |
| S | 1915-10-27 | Total score [AUDIT] | 9 | http://loinc.org · 75624-7 |
| S | 1915-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | http://loinc.org · 44261-6 |
| S | 1915-10-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | http://loinc.org · 70274-6 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1915-08-04 | Body height | 173 cm | 8302-2 | S |
| 1915-08-04 | Body weight | 84.2 kg | 29463-7 | S |
| 1915-08-04 | Body mass index (BMI) [Ratio] | 28.1 kg/m2 | 39156-5 | S |
| 1915-08-04 | Systolic blood pressure | 158 mm[Hg] | 8480-6 | S |
| 1915-08-04 | Diastolic blood pressure | 98 mm[Hg] | 8462-4 | S |
| 1915-08-04 | Heart rate | 92 /min | 8867-4 | S |
| 1915-08-04 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-08-04 | Body temperature | 36.8 Cel | 8310-5 | S |
| 1915-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1915-08-18 | Body height | 173 cm | 8302-2 | S |
| 1915-08-18 | Body weight | 83.6 kg | 29463-7 | S |
| 1915-08-18 | Body mass index (BMI) [Ratio] | 27.9 kg/m2 | 39156-5 | S |
| 1915-08-18 | Systolic blood pressure | 146 mm[Hg] | 8480-6 | S |
| 1915-08-18 | Diastolic blood pressure | 92 mm[Hg] | 8462-4 | S |
| 1915-08-18 | Heart rate | 84 /min | 8867-4 | S |
| 1915-08-18 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-08-18 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1915-09-15 | Body height | 173 cm | 8302-2 | S |
| 1915-09-15 | Body weight | 82.6 kg | 29463-7 | S |
| 1915-09-15 | Body mass index (BMI) [Ratio] | 27.6 kg/m2 | 39156-5 | S |
| 1915-09-15 | Systolic blood pressure | 138 mm[Hg] | 8480-6 | S |
| 1915-09-15 | Diastolic blood pressure | 86 mm[Hg] | 8462-4 | S |
| 1915-09-15 | Heart rate | 78 /min | 8867-4 | S |
| 1915-09-15 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-09-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1915-10-13 | Body height | 173 cm | 8302-2 | S |
| 1915-10-13 | Body weight | 81.4 kg | 29463-7 | S |
| 1915-10-13 | Body mass index (BMI) [Ratio] | 27.2 kg/m2 | 39156-5 | S |
| 1915-10-13 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 1915-10-13 | Diastolic blood pressure | 80 mm[Hg] | 8462-4 | S |
| 1915-10-13 | Heart rate | 72 /min | 8867-4 | S |
| 1915-10-13 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-10-13 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1915-10-27 | Body height | 173 cm | 8302-2 | S |
| 1915-10-27 | Body weight | 80.9 kg | 29463-7 | S |
| 1915-10-27 | Body mass index (BMI) [Ratio] | 27 kg/m2 | 39156-5 | S |
| 1915-10-27 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 1915-10-27 | Diastolic blood pressure | 78 mm[Hg] | 8462-4 | S |
| 1915-10-27 | Heart rate | 70 /min | 8867-4 | S |
| 1915-10-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-10-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1915-09-29 | Body height | 173 cm | 8302-2 | S |
| 1915-09-29 | Body weight | 82 kg | 29463-7 | S |
| 1915-09-29 | Body mass index (BMI) [Ratio] | 27.4 kg/m2 | 39156-5 | S |
| 1915-09-29 | Systolic blood pressure | 130 mm[Hg] | 8480-6 | S |
| 1915-09-29 | Diastolic blood pressure | 82 mm[Hg] | 8462-4 | S |
| 1915-09-29 | Heart rate | 74 /min | 8867-4 | S |
| 1915-09-29 | Respiratory rate | 14 /min | 9279-1 | S |
| 1915-09-29 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1915-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1915-09-01 | Body height | 173 cm | 8302-2 | S |
| 1915-09-01 | Body weight | 83.2 kg | 29463-7 | S |
| 1915-09-01 | Body mass index (BMI) [Ratio] | 27.8 kg/m2 | 39156-5 | S |
| 1915-09-01 | Systolic blood pressure | 142 mm[Hg] | 8480-6 | S |
| 1915-09-01 | Diastolic blood pressure | 88 mm[Hg] | 8462-4 | S |
| 1915-09-01 | Heart rate | 88 /min | 8867-4 | S |
| 1915-09-01 | Respiratory rate | 16 /min | 9279-1 | S |
| 1915-09-01 | Body temperature | 36.7 Cel | 8310-5 | S |
| 1915-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Novelist and journalist, internationally known; writes a thousand words every morning from nine to eleven, six or seven days a week, under steady pressure to pay for the ranch and to help others; farms and breeds livestock on a large ranch in the Sonoma Valley
- S Married; two daughters from an earlier marriage; lives on the ranch; back two weeks from five months in Hawaii
- S Drinks whisky most days: the first drink when the morning's writing is done, more through the afternoon and evening, a bottle or more on most days for years, and a drink on waking some mornings to steady his hands; has tried to cut down on his own several times; AUDIT 27
- S Smokes about ten cigarettes a day; no other substances; no opioids or sleeping pills
- S Eats one large meal a day, often rare meat, with little fruit or vegetables; heavy salt; rides and swims in the afternoons when he is well
- S Keeps a rifle and a shotgun on the ranch for livestock and hunting
- S Strengths: an iron habit of daily work, curiosity and humor, his love of the ranch and the sea, a frank and detailed understanding of his own drinking, and his own decision to come in now
Functional status
- S Independent; still writes every morning but tires by afternoon; rides less than he did; knee and low back pain after riding
Mental status
- S Alert, warm and quick; speech fluent, at times emphatic; mood 'worn down'; affect full; slight tremor of the outstretched hands; no psychotic symptoms; no thoughts of suicide or of harming anyone; insight good and judgment fair; PHQ-9 9 with item 9 scored 0; GAD-7 7
Structured safety assessment
This assessment is synthetic and does not convert historical behavior into a present-day fact.
Allergies and medications
Allergies
- S No known allergy
Medications
- S Naproxen 500 mg oral tablet twice daily, bought over the counter at full strength and taken most days for about two years for knee and back pain; stopped at intake
- S Losartan 50 mg oral tablet once daily
- S Losartan 100 mg oral tablet once daily
- S Chlordiazepoxide 25 mg oral capsule, fixed five-day taper for alcohol withdrawal (four capsules on day 1, three on day 2, two on day 3, one on days 4 and 5), dispensed for five days only, with a daily telephone check
- S Thiamine 100 mg oral tablet once daily
- S Acetaminophen 500 mg oral tablet, one or two tablets up to four times a day as needed for pain, no more than 2,000 mg in a day, in place of naproxen
- S Naltrexone 50 mg oral tablet once daily, with a wallet card warning that it blocks opioid pain medicines
- S Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily
- S Dapagliflozin 10 mg oral tablet once daily, held on any day he cannot eat or drink normally, and before surgery
- S Diclofenac 1% gel, 4 g rubbed into the outer right ankle four times a day for up to seven days, in place of any oral anti-inflammatory medicine
Procedures and immunizations
Procedures
- S Ultrasound of the abdomen and kidneys: right kidney 10.8 cm and left 11.0 cm with increased cortical echogenicity and preserved cortical thickness, no stones, no hydronephrosis, no cysts; bright liver consistent with steatosis, smooth outline, normal spleen, no ascites
- S Vibration-controlled transient elastography of the liver: median liver stiffness 7.2 kPa (interquartile range under 30 percent), controlled attenuation parameter 312 dB/m; advanced fibrosis unlikely
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 1915-09-29: Influenza vaccine, inactivated, trivalent, preservative-free, for this season
- S 1915-09-29: Pneumococcal conjugate vaccine (PCV20), single dose
- S 1915-09-29: Hepatitis B vaccine (HepB-CpG), first of two doses
- S 1915-09-29: Hepatitis A vaccine, adult, first of two doses
- S 1915-10-27: Hepatitis B vaccine (HepB-CpG), second of two doses
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1897 to 1898: Scurvy in the gold fields in his early twenties; recovered (CLM-0003)
- R 1907 to 1909: Skin sores, swollen and peeling hands and feet, and a silvery skin during a long Pacific voyage, with five weeks in hospital; the hands recovered and the skin cleared without treatment; the diagnoses were never settled (CLM-0006, CLM-0007)
- D July 1913: Appendectomy, at which kidney damage was found (CLM-0009)
- D 1914: Dysentery and joint pain (described as rheumatism) while working abroad (CLM-0010)
Family history
No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| Find out how much kidney function is lost, how long it has been so, and why | 1915-08-18 | completed | Chronic kidney disease G3b A2 from hypertension with naproxen contributing; no stones, obstruction or glomerular disease suspected |
| Stop drinking safely, and stay stopped | 1916-02-02 | active | Withdrawal completed without complications; one evening of drinking at four weeks; abstinent since, with PEth 8 and then 6 ng/mL |
| Blood pressure below 120 systolic by standardized office measurement if tolerated, and at least below 130/80 | 1916-02-02 | active | 158/98 to 122/78 at twelve weeks on losartan 100 mg |
| Urine albumin down by at least 30 percent | 1915-10-27 | completed | 240 to 96 mg/g on losartan and then dapagliflozin |
| No anti-inflammatory pain medicines, and pain controlled | 1915-10-27 | completed | No naproxen since intake; acetaminophen and topical treatment only, including for an ankle sprain |
| Keep the morning writing hours | 1915-10-27 | completed | Wrote every morning through the twelve weeks except the two days of the worst withdrawal |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Kidneys and blood pressure: creatinine with eGFR (CKD-EPI 1910), urine albumin-to-creatinine ratio and urinalysis with microscopy, electrolytes and bicarbonate, uric acid, calcium, phosphate and PTH, blood count, HbA1c and a lipid panel once; the earlier insurance creatinine obtained; ultrasound of the kidneys and liver; standardized office blood pressure at every visit and home readings | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021, GL-CMID-2026 |
| Nephrology consultation to confirm the stage and cause of the kidney disease and advise on blood pressure, an SGLT2 inhibitor, medicines for alcohol use disorder at his kidney function, and pain relief | completed | GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 |
| Losartan 50 mg daily from intake, raised to the maximum tolerated dose, with potassium and creatinine two to four weeks after each start or change, accepting a rise in creatinine of up to 30 percent; less salt | completed | GL-KDIGO-BP-2021, GL-AHA-HTN-2025, GL-CMID-2026 |
| Alcohol: AUDIT, DSM-5-TR criteria and PEth with consent; liver tests and FIB-4; a withdrawal-risk score (PAWSS) and outpatient withdrawal with a five-day chlordiazepoxide taper, daily telephone checks and thiamine; addiction-focused counseling with the clinic's addiction medicine team each week and mutual-help meetings if he wishes; PEth and liver tests at follow-up | completed | GL-APA-AUD-2018, GL-SUD-2021, GL-ASAM-AWM-2020, GL-AASLD-NIT-2025 |
| Medicine for alcohol use disorder: naltrexone 50 mg daily, which needs no dose change at his kidney function, with liver tests and a wallet card about opioid blockade; acamprosate not chosen because it needs a lower dose at his creatinine clearance and is avoided below 30 mL/min, and he could not reliably take it three times a day | completed | GL-APA-AUD-2018, GL-SUD-2021, GL-KDIGO-CKD-2024 |
| Liver: ultrasound and vibration-controlled transient elastography for an indeterminate FIB-4; abstinence as the treatment | completed | GL-AASLD-ALD-2019, GL-AASLD-NIT-2025 |
| SGLT2 inhibitor (dapagliflozin 10 mg daily) once he has been abstinent for some weeks and is eating regularly, because heavy drinking and fasting raise the risk of ketoacidosis; held on days he cannot eat or drink, with potassium and creatinine two to four weeks after starting, accepting an early fall in eGFR | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 |
| Pain and medicine safety: no naproxen, ibuprofen or other oral anti-inflammatory medicines; acetaminophen up to 2,000 mg a day; no opioids or tramadol with kidney disease and in early recovery, and none at all if naltrexone is started; any new medicine checked for kidney dosing | completed | GL-KDIGO-CKD-2024, GL-CMID-2026 |
| Safety: a structured safety assessment, firearms locked with ammunition apart, small supplies of withdrawal medicine, a written safety plan, the 988 Suicide & Crisis Lifeline, and safety review at every visit | completed | GL-SUICIDE-2024, GL-USPSTF-DEP-2023 |
| Work and recovery: keep the morning writing hours from nine to eleven; replace the late-morning drink with a swim or a ride; no alcohol kept in the writing room; PHQ-9 and GAD-7 at intake and follow-up | completed | GL-SUD-2021, GL-USPSTF-DEP-2023 |
| Tobacco: advice to stop, with nicotine replacement or varenicline offered when he is ready | completed | GL-USPSTF-TOB-2021 |
Planned encounters
- 1915-08-04 — Establishing care for tiredness and ankle swelling, with high blood pressure and abnormal kidney tests, and heavy drinking found at the visit: kidney, liver and alcohol tests, AUDIT and DSM-5-TR assessment, withdrawal planning, mood and safety, his writing schedule, and a nephrology consultation (ENC-001)
- 1915-08-18 — Two-week review after stopping alcohol and starting losartan, seen the same day by nephrology: kidney staging and cause, ultrasound and elastography, blood pressure target, medicine for alcohol use disorder, and pain relief (ENC-002)
- 1915-09-01 — Same-day sick visit for a right ankle sprain (ENC-007, unscheduled)
- 1915-09-15 — Six-week review: drinking and PEth, blood pressure, potassium and creatinine, urine albumin, liver tests, mood and safety (ENC-003)
- 1915-09-29 — Periodic adult preventive visit (ENC-006)
- 1915-10-13 — Ten-week review: abstinence, potassium and creatinine after the losartan increase, and the SGLT2 inhibitor (ENC-004)
- 1915-10-27 — Twelve-week review: kidney function after the SGLT2 inhibitor, urine albumin, liver tests, AUDIT, mood, safety and the plan ahead (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Sick Visit
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Preventive Visit
- Progress note 06 — Focused Visit (Follow-up)
- Progress note 07 — Focused Visit (Care-plan review)
- Nephrology referral
- Nephrology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Sick Visit (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Preventive Visit (XML)
- Progress note 06 — Focused Visit (Follow-up) (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Nephrology referral (XML)
- Nephrology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the CKD staging (G3b A2) and the attribution to hypertension and naproxen without a biopsy, losartan to the maximum dose with potassium checks, the systolic target, the delay of dapagliflozin until abstinence because of ketoacidosis risk, naltrexone over acamprosate at his kidney function, outpatient chlordiazepoxide withdrawal, the elastography interpretation, no treatment of asymptomatic high uric acid, the analgesic plan and the topical diclofenac for the sprain, the safety assessment and firearm storage, and the vaccinations. |
| provenance review | not_started | Sources: Jack London State Historic Park (the biography and three park historian or docent documents, one citing the death certificate and Huntington Library correspondence), California State Parks, his own accounts in The Cruise of the Snark and John Barleycorn (Project Gutenberg), and the PubMed records of Bomback and Klemmer (2007, 2008), Denko (1993) and Aronica and Norton (2015). The Huntington Library, Sonoma State University and Library of Congress pages could not be read. The roster's depression and probable bipolar disorder are not used as diagnoses. |
| safe messaging review | not_started | Alcohol, mood and the disputed morphine and suicide story are marked sensitive. The morphine question is recorded once, plainly, as disputed later history, with neither side adopted, and is not used in the modern episode or shown in the intake documents. His drinking is described in his own published words and the modern alcohol use disorder is synthetic. A structured safety assessment with lethal-means counseling and the 988 line is recorded, and safety is reviewed at every visit. His relatives appear only as documented history; no relative has a role in the modern episode. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.